Is Teoclato de prometazina Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Teoclato de prometazina? Is Teoclato de prometazina safe for nursing mother and child? Does Teoclato de prometazina extracts into breast milk? Does Teoclato de prometazina has any long term or short term side effects on infants? Can Teoclato de prometazina influence milk supply or can Teoclato de prometazina decrease milk supply in lactating mothers?
Teoclato de prometazina lactation summary
- DrLact safety Score for Teoclato de prometazina is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Teoclato de prometazina may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Teoclato de prometazina may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Teoclato de prometazina low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Teoclato de prometazina We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Teoclato de prometazina usage in lactation
1st-generation-antihistamine and phenothiazine-type drug with a strong sedative effect. At latest update relevant published data on excretion into breast milk were not found. It may decrease prolactin levels and interfere with milk production during the first few weeks after birth (Pontiroli 1981, Messinis 1985).Pharmacokinetic data (high volume of distribution and high plasma protein-binding capacity) would render it unlikely a significant passage into the breastmilk.In addition, a low oral bioavailability would hinder a further passage to infant’s plasma through the ingested breastmilk, except on premature infants and immediate neonatal period when there may be an increased intestinal permeability.There are doubts about any association with Sudden Infant Death Syndrome (SIDS) (Kahn 1982, Stanton 1983). It may be considered compatible with breastfeeding on isolated doses such as those used for pre-surgical medication or traveler's dizziness (WHO 2002). Avoid a repeated use as it may cause drowsiness in the infant.Avoid using it in the immediate neonatal period (first 4 to 6 weeks after birth) and in case of prematurity. If used, follow-up the infant for drowsiness and feeding issues. It is not recommended bed-sharing when taking this medication (UNICEF 2006, ABM 2008, Landa 2012, UNICEF 2013).